Statement by Mr. François Hollande, President of the Republic, on vaccine research in the face of emerging diseases, in Paris on February 21, 2017.

France François Hollande · President of France

21 February 2017 · Vaccine research in the face of emerging diseases meeting · Paris, France

Context
Hollande addressed an international meeting in Paris on vaccine research and emerging diseases, outlining France's scientific, financial, and strategic commitments to epidemic preparedness.
Main themes
Vaccine research and development, emerging infectious diseases, epidemic preparedness, CEPI and global health partnerships, Ebola epidemic, Zika virus, public-private partnerships in health research, GAVI and global vaccine funding, France's global health commitments, population acceptance of vaccines, scientific challenges in virology, REACTing consortium and INSERM
Duration
~11 min
39th percentile
Words
1,343
39th percentile
Sentences
48
31st percentile
Readability
41
39th percentile
Grade
14.4
71st percentile
Syntax
3.27
80th percentile
Vocabulary
2.23
56th percentile

Translated from French

Content
Actors
Style

The broad sphere of national life a sentence belongs to. Every sentence has an Arena, so it is the denominator the other indices are read against.

Other
  • Social 64%58%
  • Institutional 11%10%
  • Ceremonial 11%10%
  • Economic 9%8%
  • Geopolitical 5%4%
  • Technological 0%0%
  • Environmental 0%0%
  • Not in focus 8%

48 sentences in 20 paragraphs

Mr. President, Dear Yves LEVY,

Mr. Special Advisor, Dr. Thore GOGAL,

Mr. Deputy Director, Dr. Frédérik KRISTENSEN,

Mr. President of the University, Mr. DARDEL,

Ladies and Gentlemen, I wanted to be among you for this meeting because I understand the stakes involved.

As Mr. Yves LEVY mentioned, I had the opportunity to witness the consequences of an epidemic. I indeed traveled to Guinea during what was the most serious health crisis in recent years, when the Ebola virus could destroy entire families and threaten lives. I would like to remind you that there were over 11,000 deaths as a result of this epidemic, 25 times more than during the previous 40 years. And it took more than three years for the situation to finally be brought under control.

From this human tragedy, we drew a conclusion that our world is not sufficiently prepared to fight against epidemics. We also became aware that, everywhere in the world, in the South as well as in the North, there was the emergence of possible localized epidemics or a pandemic whose mortality could be unpredictable, while morbidity could affect not only the immediately impacted generations but also the next generation, as we unfortunately observed with the Zika virus epidemic, where very serious anomalies appeared in children who were first infected.

So today’s meeting aims to reflect on the strategy that must be ours to face these emerging diseases, and the use and research of vaccines; it is about both preventing the spread of the disease when it is established and also preventing the development of the infection, and even anticipating it by detecting threats. In this perspective, the organization and coordination of research are paramount, and it is France's role to organize itself through the REACTing consortium, led by INSERM.

But I must also be lucid and clear. The fight against emerging diseases primarily relies on vaccines, and this is the subject that CEPI and INSERM have decided to address. I want to commend the role of CEPI in the development of new vaccines, and CEPI is in a way a bridge between WHO and GAVI, to ensure continuity between the definition of a vaccination policy and the effective delivery of vaccines.

We must also ensure, as you insisted, and you were right, that the costs of vaccine development do not become obstacles that could undermine our health ambitions. France must play its full part in this, and at the same time as we reaffirm France's commitments through the Global Fund, we also wanted to contribute financially to GAVI, to the tune of 280 million dollars. For the period 2016-2020, the partnership between GAVI, the Gates Foundation, and the French Development Agency will allow France to contribute 100 million euros to this policy in favor of Sahel countries.

We are also aware that populations, as we have seen again in Guinea and in other countries, are not necessarily prepared to accept vaccines. So producing vaccines, finding vaccines, all of this is necessary, but it is not sufficient, and we must respect the habits of the populations, know them, and also explain to these populations, tirelessly, and even before the crisis reappears, what the benefits of using vaccines are, and thus make them acceptable.

Your meeting today also allows us to reflect on the challenges that lie ahead, and I can identify three of these challenges. First, the scientific challenge; you reminded us that science has identified more than 20 potentially dangerous infectious agents, for which we have neither medicines nor vaccines. We must undoubtedly establish vaccine platforms, as proposed by the Secretary-General of the United Nations in June 2016, in order to rationalize and optimize research, but we can clearly see that the issue is research.

And we cannot leave the world in a state of uncertainty; there is already enough of that, in risks that have not been anticipated, and we would be criticized both as political leaders and as those in research organizations for not having anticipated, not having prepared, and not having - after the identification of these infectious agents - established a vaccination strategy. This is the first challenge we must meet.

The second is necessarily financial and economic. Economic, because preventing health crises is the best way to ensure social cohesion, and we can clearly see what Ebola has disrupted in the economies of the countries affected by the virus.

So, beyond this economic issue, there is the financial issue, because research will advance all the faster if we can establish partnerships between public and private sectors; this was the case with the PREVAC and EBOVAC actions carried out in Guinea, Liberia, Sierra Leone, and Burkina Faso, and INSERM was the partner of these industries. And we are very committed to ensuring that we can have this trust between public research organizations and private partners, who must be absolutely involved, and this is the meaning of CEPI's commitment. That is why we attach great importance to it.

The third challenge - I would say - is ethical. How to reconcile the promotion of innovation and access to expensive medicines, ensuring that health systems can be sustainable, while at the same time offering those affected by a disease - especially if it is emerging - the conditions for care and healing? This is a moral problem, because it is not only posed in Northern countries; it is posed everywhere in the world. How can we accept that a family living in complete destitution, who nevertheless has access to all information through the Internet, can understand that they cannot benefit from the treatment that has been invented, on the grounds that it is too expensive?

We can imagine what uprisings could occur in many countries in the face of this inequality. How can we accept that people are treated in the North and not in the South, simply for financial reasons? This question also arises in developed countries, and it is a decision that must be made at the highest levels of government, to determine what should be reimbursed, what should not be, and above all, what must be accessible to all, including when it comes to extremely expensive treatments. At what age can one still benefit from it, under what conditions, who decides? These are the ethical challenges that are posed.

I wanted this question to be addressed in international meetings, particularly at the G7 - this was the case in May 2016 - when I indeed delivered a speech in Lyon, with President ZUMA, so that we could act together, and that the relevant health ministries could organize themselves in relation to such an issue. This working group met last January and will produce its conclusions, but we must emphasize that this is surely one of the major themes of what international negotiations will be in the coming years.

How to have a health system on a global scale, how to ensure that there can be a research policy that is also decided at a global level? How to ensure that the population can be confident that treatments will be provided to them under acceptable conditions? And how to prevent, how to act before it is too late? This is the whole question of vaccination strategies that is thus posed; by addressing emerging diseases and vaccines, you contribute to providing essential elements for this debate to be animated, and above all resolved.

So, I wanted, by my presence here at your meeting, to confirm what France's position is, to tell you that we consider the issue you are addressing to be essential for security, here, health security, in my country, but also on an international scale, and that at a time when there is a retreat into oneself, where there is a temptation to think that there can be walls, that borders can be erected that could never be crossed, if there is one demonstration we can provide, it is that in matters of epidemics, we can build walls, even ask neighbors to finance them, the disease will come anyway. Thank you.